Study to Assess the Safety and Efficacy of ISIS 301012 (Mipomersen) in Homozygous Familial Hypercholesterolemia
Status:
Completed
Trial end date:
2009-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of mipomersen (ISIS 301012)
in subjects with homozygous familial hypercholesterolemia on lipid-lowering therapy.
This study consisted of a 26-week treatment period and a 24-week post-treatment follow-up
period. Following treatment and Week 28 evaluations, participants could elect to enroll in an
open-label extension study (301012-CS6; NCT00694109). Participants who were not eligible or
elected not to enroll in the open-label extension study or who discontinued during the
28-week treatment period were followed in this study for 24 weeks from administration of the
last dose of study drug.